These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15593443)

  • 1. Results of tigecycline trials announced.
    McConnell J
    Lancet Infect Dis; 2004 Dec; 4(12):717. PubMed ID: 15593443
    [No Abstract]   [Full Text] [Related]  

  • 2. Tigecycline: place in therapy and important considerations.
    Garrelts JC; Schroeder T
    Am J Health Syst Pharm; 2006 Jul; 63(13):1233. PubMed ID: 16790574
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tigecycline: antimicrobial action, chemotherapeutic efficacy and adverse reactions].
    Nikitin AV
    Antibiot Khimioter; 2009; 54(1-2):63-6. PubMed ID: 19499721
    [No Abstract]   [Full Text] [Related]  

  • 5. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tigecycline--a new antibiotic].
    Skibeli V; Aaløkken I; Lingaas E; Midtvedt T; Solberg CO; Melby KK
    Tidsskr Nor Laegeforen; 2010 Aug; 130(16):1624-6. PubMed ID: 20805861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
    Johnson AP; Leibovici L
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness and safety of tigecycline: focus on use for approved indications.
    Vardakas KZ; Rafailidis PI; Falagas ME
    Clin Infect Dis; 2012 Jun; 54(11):1672-4. PubMed ID: 22431809
    [No Abstract]   [Full Text] [Related]  

  • 9. Tigecycline: an antibiotic for the twenty-first century.
    Dryden M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antibiotic approved for MRSA.
    Senior K
    Lancet Infect Dis; 2005 Aug; 5(8):474. PubMed ID: 16094734
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
    Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
    Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline: benefits and risks.
    Cai Y; Wang R
    Lancet Infect Dis; 2011 Nov; 11(11):804-5. PubMed ID: 21784707
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline.
    Nicolau DP
    Expert Opin Pharmacother; 2009 May; 10(7):1213-22. PubMed ID: 19405794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
    Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
    Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
    Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
    J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a critical update.
    Shakil S; Akram M; Khan AU
    J Chemother; 2008 Aug; 20(4):411-9. PubMed ID: 18676218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tigecycline in the treatment of infections in light of the new black box warning.
    Dixit D; Madduri RP; Sharma R
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):397-400. PubMed ID: 24597542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.